Compare DECK & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DECK | BIIB |
|---|---|---|
| Founded | 1973 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4B | 24.2B |
| IPO Year | 1993 | 1991 |
| Metric | DECK | BIIB |
|---|---|---|
| Price | $99.39 | $181.61 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 23 |
| Target Price | $121.63 | ★ $176.48 |
| AVG Volume (30 Days) | ★ 3.5M | 1.9M |
| Earning Date | 10-23-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.83 | N/A |
| EPS | 6.75 | ★ 10.97 |
| Revenue | $5,244,323,000.00 | ★ $10,065,900,000.00 |
| Revenue This Year | $9.84 | $3.61 |
| Revenue Next Year | $7.36 | N/A |
| P/E Ratio | ★ $14.77 | $16.52 |
| Revenue Growth | ★ 12.62 | 4.77 |
| 52 Week Low | $78.91 | $110.04 |
| 52 Week High | $223.98 | $185.17 |
| Indicator | DECK | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 67.87 | 72.92 |
| Support Level | $81.40 | $174.53 |
| Resistance Level | $86.09 | $182.94 |
| Average True Range (ATR) | 3.00 | 5.22 |
| MACD | 2.31 | 0.25 |
| Stochastic Oscillator | 99.97 | 83.54 |
Founded in 1973, California-based Deckers designs and sells casual and performance footwear, apparel, and accessories. In fiscal 2025, Ugg and Hoka accounted for 51% and 45% of total sales, respectively. The firm also markets niche brands Teva and Ahnu. Deckers produces most of its sales through wholesale partnerships but also operates e-commerce in more than 50 countries and has nearly 200 company-operated stores. It generated 64% of its fiscal 2025 sales in the United States.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).